ASCP Corner: Real-Life Dosing With Second-Generation Antipsychotics
J Clin Psychiatry 2005;66(12):1610-1611
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
This is the first of 2 articles addressing
methodological issues regarding real-life
dosing and switching strategies when
treating patients with second-generation
When faced with nonresponse to an adequate
duration of antipsychotic treatment
at maximum recommended doses, clinicians
have 4 basic options to improve
symptomatic and/or functional response:
(1) wait for the occurrence of a potentially
delayed response; (2) augment with another
medication (of the same or a different
class); (3) switch to another medication
(of the same or a different class); or
(4) increase the dose beyond the upper
dose range used in U.S. Food and Drug
Administration (FDA) approval trials. If
sufficient data were available, a fifth option
could be to check for the presence of
therapeutic antipsychotic drug levels.